SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023)

被引：2

作者：

Perez-Fidalgo, Jose Alejandro ^{[1
]}

Galvez-Montosa, Fernando ^{[2
]}

Guerra, Eva Maria ^{[3
]}

Madariaga, Ainhoa ^{[4
]}

Manzano, Aranzazu ^{[5
]}

Martin-Lorente, Cristina ^{[6
]}

Rubio-Perez, Maria Jesus ^{[7
]}

Alarcon, Jesus ^{[8
]}

Barretina-Ginesta, Maria Pilar ^{[9
]}

Gaba, Lydia ^{[10
]}

机构：

[1] Univ Valencia, Hosp Clin Univ, Biomed Res Inst INCL, Valencia, Spain

[2] Hosp Univ Jaen, Jaen, Spain

[3] Hosp Univ Ramon y Cajal, Madrid, Spain

[4] 12 Octubre Univ Hosp, Dept Med Oncol, Madrid, Spain

[5] Hosp Clin San Carlos, Madrid, Spain

[6] Hosp Santa Creu & Sant Pau, Radiol, Barcelona, Spain

[7] Univ Cordoba UCO, Hosp Univ Reina Sofia, Cordoba, Spain

[8] Hosp Univ Son Espases, Mallorca, Spain

[9] Univ Girona, Inst Invest Biomed Girona IDIBGI, Med Sci Dept, Inst Catala Oncol,Med Oncol Dept,Precis Oncol Grp, Girona, Spain

[10] Univ Barcelona, Hosp Clin, Translat Genom & Targeted Therapies Solid Tumors, Med Oncol Dept,IDIBAPS,Dept Med, Barcelona, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2024年 / 26卷 / 11期

关键词：

Ovarian cancer; Guideline; Diagnosis; Treatment; PEGYLATED LIPOSOMAL DOXORUBICIN; OPEN-LABEL; MAINTENANCE THERAPY; DOUBLE-BLIND; SECONDARY CYTOREDUCTION; PLUS BEVACIZUMAB; RECURRENT; CHEMOTHERAPY; MULTICENTER; OLAPARIB;

D O I：

10.1007/s12094-024-03531-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In recent years, the incorporation of new strategies to the therapeutic armamentarium has completely changed the outcomes of epithelial ovarian cancer (EOC). The identification of new predictive and prognostic biomarkers has also enabled the selection of those patients more likely to respond to targeted agents. Nevertheless, EOC is still a highly lethal disease and resistance to many of these new agents is common. The objective of this guideline is to summarize the most relevant strategies to manage EOC, to help the clinician throughout the challenging diagnostic and therapeutic processes and to provide evidence-based recommendations.

引用

页码：2758 / 2770

页数：13

共 50 条

[1] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, Robert A.
Brady, Mark F.
Bookman, Michael A.
Fleming, Gini F.
Monk, Bradley J.
Huang, Helen
Mannel, Robert S.
Homesley, Howard D.
Fowler, Jeffrey
Greer, Benjamin E.
Boente, Matthew
Birrer, Michael J.
Liang, Sharon X.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) : 2473 - 2483
[2] The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group study
Chan, John K.
Tian, Chunqiao
Fleming, Gini F.
Monk, Bradley J.
Herzog, Thomas J.
Kapp, Daniel S.
Bell, Jeffrey
[J]. GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : 301 - 306
[3] Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
Clamp, Andrew R.
James, Elizabeth C.
McNeish, Iain A.
Dean, Andrew
Kim, Jae-Weon
O'Donnell, Dearbhaile M.
Hook, Jane
Coyle, Christopher
Blagden, Sarah
Brenton, James D.
Naik, Raj
Perren, Tim
Sundar, Sudha
Cook, Adrian D.
Gopalakrishnan, Gosala S.
Gabra, Hani
Lord, Rosemary
Dark, Graham
Earl, Helena M.
Hall, Marcia
Banerjee, Susana
Glasspool, Rosalind M.
Jones, Rachel
Williams, Sarah
Swart, Ann Marie
Stenning, Sally
Parmar, Mahesh
Kaplan, Richard
Ledermann, Jonathan A.
[J]. LANCET, 2019, 394 (10214) : 2084 - 2095
[4] Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Coleman, Robert L.
Oza, Amit M.
Lorusso, Domenico
Aghajanian, Carol
Oaknin, Ana
Dean, Andrew
Colombo, Nicoletta
Weberpals, Johanne, I
Clamp, Andrew
Scambia, Giovanni
Leary, Alexandra
Holloway, Robert W.
Amenedo Gancedo, Margarita
Fong, Peter C.
Goh, Jeffrey C.
O'Malley, David M.
Armstrong, Deborah K.
Garcia-Donas, Jesus
Swisher, Elizabeth M.
Floquet, Anne
Konecny, Gottfried E.
McNeish, lain A.
Scott, Clare L.
Cameron, Terri
Maloney, Lara
Isaacson, Jeff
Goble, Sandra
Grace, Caroline
Harding, Thomas C.
Raponi, Mitch
Sun, James
Lin, Kevin K.
Giordano, Heidi
Ledermann, Jonathan A.
[J]. LANCET, 2017, 390 (10106) : 1949 - 1961
[5] Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Coleman, Robert L.
Brady, Mark F.
Herzog, Thomas J.
Sabbatini, Paul
Armstrong, Deborah K.
Walker, Joan L.
Kim, Byoung-Gie
Fujiwara, Keiichi
Tewari, Krishnansu S.
O'Malley, David M.
Davidson, Susan A.
Rubin, Stephen C.
DiSilvestro, Paul
Basen-Engquist, Karen
Huang, Helen
Chan, John K.
Spirtos, Nick M.
Ashfaq, Raheela
Mannel, Robert S.
[J]. LANCET ONCOLOGY, 2017, 18 (06) : 779 - 791
[6] INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
Colombo, N.
Gadducci, A.
Sehouli, J.
Rulli, E.
Maenpaa, J.
Sessa, C.
Montes, A.
Ottevanger, N. B.
Berger, R.
Vergote, I.
D'Incalci, M.
Galaz, C. Churruca
Chekerov, R.
Nyvang, G. B.
Riniker, S.
Herbertson, R.
Fossati, R.
Barretina-Ginesta, M. P.
Deryal, M.
Mirza, M. R.
Biagioli, E.
Iglesias, M.
Funari, G.
Romeo, M.
Tasca, G.
Pardo, B.
Tognon, G.
Rubio-Perez, M. J.
DeCensi, A.
De Giorgi, U.
Zola, P.
Panici, P. Benedetti
Aglietta, M.
Arcangeli, V.
Zamagni, C.
Bologna, A.
Westermann, A.
Heinzelmann-Schwarz, V.
Tsibulak, I.
Wimberger, P.
Poveda, A.
[J]. BRITISH JOURNAL OF CANCER, 2023, 128 (08) : 1503 - 1513
[7] Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
DiSilvestro, Paul
Banerjee, Susana
Colombo, Nicoletta
Scambia, Giovanni
Kim, Byoung-Gie
Oaknin, Ana
Friedlander, Michael
Lisyanskaya, Alla
Floquet, Anne
Leary, Alexandra
Sonke, Gabe S.
Gourley, Charlie
Oza, Amit
Gonzalez-Martin, Antonio
Aghajanian, Carol
Bradley, William
Mathews, Cara
Liu, Joyce
McNamara, John
Lowe, Elizabeth S.
Ah-See, Mei-Lin
Moore, Kathleen N.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 609 - +
[8] Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)
du Bois, Andreas
Reuss, Alexander
Pujade-Lauraine, Eric
Harter, Philipp
Ray-Coquard, Isabelle
Pfisterer, Jacobus
[J]. CANCER, 2009, 115 (06) : 1234 - 1244
[9] Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study
Falandry, Claire
Pommeret, Fanny
Gladieff, Laurence
Tinquaut, Fabien
Lorusso, Domenico
Mouret-Reynier, Marie-Ange
D'Hondt, Veronique
Mollon-Grange, Delphine
Floquet, Anne
Abadie-Lacourtoisie, Sophie
Brachet, Pierre-Emmanuel
Stefani, Laetitia
Rousseau, Frederique
Frenel, Jean-Sebastien
Del Piano, Francesco
Komulainen, Marja
Warkus, Thomas
Tredan, Olivier
Pujade-Lauraine, Eric
Freyer, Gilles
[J]. LANCET HEALTHY LONGEVITY, 2022, 3 (03): : E176 - E185
[10] Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update
Fotopoulou, Christina
Concin, Nicole
Planchamp, Francois
Morice, Philippe
Vergote, Ignace
du Bois, Andreas
Querleu, Denis
[J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (04) : 436 - 440

← 1 2 3 4 5 →